



Annual Progress Report 2007

Submitted by

The Government of

NICARAGUA

Date of submission: June 16th, 2008

Deadline for submission 15 May 2008

(to be accompanied with Excel sheet as prescribed)

Please return a signed copy of the document to:
GAVI Alliance Secretariat; c/o UNICEF, Palais des Nations, 1211 Geneva 10, Switzerland.

Enquiries to: Dr Raj Kumar, raj कुमार@gavialliance.org or representatives of a GAVI partner agency. All documents and attachments must be in English or French, preferably in electronic form. These can be shared with GAVI partners, collaborators and general public.

This report reports on activities in 2007 and specifies requests for January – December 2009

Signatures Page for ISS, INS and NVS

For the Government of Republic of Nicaragua

Ministry of Health:

Title: Minister Dr. Guillermo Gonzalez

Signature:

Date: 16/06/2008



Ministry of Finance:

Title:

Signature:

Date:

We, the undersigned members of the Inter-Agency Co-ordinating Committee endorse this report, including the attached excelsheet. Signature of endorsement of this document does not imply any financial (or legal) commitment on the part of the partner agency or individual.

Financial accountability forms an integral part of GAVI Alliance monitoring of reporting of country performance. It is based on the regular government audit requirements as detailed in the Banking form.

The ICC Members confirm that the funds received from the GAVI Funding Entity have been audited and accounted for according to standard government or partner requirements.

Name/Title	Agency/Organisation	Signature	Date
Dr. Alejandro Solis Director of Planning and Development	Ministry of Health		10/06/2008
Dr. Omar Malespin Director of Expanded Program of Immunization	Ministry of Health		10/06/2008
Sra. Maria Machicado Representative a.i	UNICEF		11/06/2008
Dr. Merlin Fernández Representative a.i. in Nicaragua	OPS/OMS		16/06/2008
Dra. Cristina Pedreira Expanded Program of Immunization Consultant	OPS/OMS		12/06/2008
Dr. José Enrique Solis President	Nicaraguan Pediatric Society		13/06/2008
Dr. Alfonso Matus President	National Committee of Immunization Practice		13/06/2008

Progress Report Form: Table of Contents

1. Report on progress made during 2007

- 1.1 Immunization Services Support (ISS)**
 - 1.1.1 Management of ISS Funds
 - 1.1.2 Use of Immunization Services Support
 - 1.1.3 Immunization Data Quality Audit
 - 1.1.4 ICC Meetings
- 1.2 GAVI Alliance New and Under-used Vaccines (NVS)**
 - 1.2.1 Receipt of new and under-used vaccines
 - 1.2.2 Major activities
 - 1.2.3 Use if GAVI Alliance financial support (US\$100,000) for introduction of the new vaccine
 - 1.2.4 Evaluation of Vaccine Management System
- 1.3 Injection Safety (INS)**
 - 1.3.1 Receipt of injection safety support
 - 1.3.2 Progress of transition plan for safe injections and safe management of sharps waste
 - 1.3.3 Statement on use of GAVI Alliance injection safety support (if received in the form of a cash contribution)

2. Vaccine Co-financing, Immunization Financing and Financial Sustainability

3. Request for new and under-used vaccine for 2009

- 3.1 Up-dated immunization targets**
- 3.2 Confirmed/revised request for new vaccine (to be shared with UNICEF Supply Division) for year 2009 and projections for 2010 and 2011**
- 3.3 Confirmed/revised request for injection safety support for the year 2009 and 2010**

4. Health System Strengthening (HSS)

5. Checklist

6. Comments

Text boxes supplied in this report are meant only to be used as guides. Please feel free to add text beyond the space provided.

1.3 Injection Safety

1.3.1 Receipt of injection safety support

Received in cash/kind

Please report on receipt of injection safety support provided by the GAVI Alliance during 2007 (add rows as applicable).

Injection Safety Material	Quantity	Date received
Becton Dickinson / AD syringes, ½ cc, 23 G x 1	902,400	19. April.2007
Becton Dickinson / AD syringes, 0.1cc, 27G x 3/8	180,000	02.March.2007
Becton Dickinson / AD syringes, ½ cc 25G x 5/8	170,400	03.April.2007
Becton Dickinson / AD syringes, 1cc, 23G x 1	1,092,000	20.April.2007
Becton Dickinson / AD syringes, 1/2 cc, 25G x 5/8	232,800	07.Sept.2006
Becton Dickinson / AD syringes, 0.1cc, 27G x 3/8	221,600	13.Nov.2006
Safety box	24,725	20.Oct.2006
Disposable syringes 5cc	683,200	11.Oct.2006

Please report on any problems encountered.

No problem was encountered.

1.3.2. Progress of transition plan for safe injections and management of sharps waste.

If support has ended, please report how injection safety supplies are funded.

This project ends in 2008 and the country has sufficient syringes for at least two more years. Because of the expiration date, the AD syringes will start to be used only in the next year. The EPI is using the disposable syringes first, as they have earlier expiration date than the AD syringes. All safety boxes were distributed to the units of health.

Please report how sharps waste is being disposed of.

For the sharp waste, the Ministry of Health, through the National Immunization Program, recommends the utilization of boxes of safety. Currently, all the vaccination services have this resource.

For the final disposable of vaccination waste, the Ministry of Health recommends the incineration, where is available this resource. How mentioned in the last inform, there are 5 incinerators in different departments: Matagalpa, Managua (out of the capital), Chinandega, Granada, León. Furthermore, there are incinerators in some of the principal hospitals of Managua City.

Wherever there are no resources for incineration, the program recommends to burn the waste.

Please report problems encountered during the implementation of the transitional plan for safe injection and sharps waste.

As previously mentioned, the AD syringes were not introduced in the regular program but the majority of EPI personnel in vaccination services of Nicaragua know how to use them, because they have some pervious experience. For the next year, 2008, the EPI program is planning a course about maintenance of

the cold chain and use of AD syringes.

The safety boxes are used in all health units as well in activities of vaccination in field, in regular program or vaccination campaign.

1.3.3. Statement on use of GAVI Alliance injection safety support in 2007 (if received in the form of a cash contribution)

The following major areas of activities have been funded (specify the amount) with the GAVI Alliance injection safety support in the past year:

To the date we have received \$432,000. A total of \$269,815.06 were designated for the purchases of syringes and safety box, related with the 2 first years of the project. At present, there is a balance of \$162,185.00, which will finance the purchase of the last year of the Project.

Table 5: Update of immunization achievements and annual targets. Provide figures as reported in the JRF in 2007 and projections from 2008 onwards.

Number of	Achievements and targets									
	2006	2007*	2008*	2009*	2010*	2011	2012	2013	2014	2015
DENOMINATORS										
Births	149,709	136,160	137,437	138,558	139,122	139,818	140,516	141,219	141,925	142,635
Infants' deaths	2085	1117	1250	1321	1309	1316	1322	1329	1335	1342
Surviving infants	147,624	135,043	136,187	137,237	137,813	138,502	139,194	139,890	140,590	141,292
Infants vaccinated till 2007 (JRF) / to be vaccinated in 2008 and beyond with 1 st dose of DTP (DTP1)*	139,905	142,770	137,437	138,558	139,122	139,818	140,516	141,219	141,925	142,635
Infants vaccinated till 2007 (JRF) / to be vaccinated in 2008 and beyond with 3 rd dose of DTP (DTP3)*	130,550	137,361	130,566	131,630	132,166	132,827	133,490	134,158	134,828	135,503
NEW VACCINES **										
Infants vaccinated till 2007 (JRF) / to be vaccinated in 2008 and beyond with 1 st dose of DTP (DTP1)* (new vaccine)										
Infants vaccinated till 2007 (JRF) / to be vaccinated in 2008 and beyond with 3 rd dose of..... (new vaccine)										
Wastage rate till 2007 and plan for 2008 beyond*** (new vaccine)										
INJECTION SAFETY****										
Pregnant women vaccinated / to be vaccinated with TT (at least one dosis)	132,973	136,537	142,044	143,898	145,744	147,494	ND	ND	ND	ND
Infants vaccinated / to be vaccinated with BCG	150,443	136,159	136,551	138,558	139,122	139,818	140,516	141,219	141,925	142,635
Infants vaccinated / to be vaccinated with Measles (1 st dose)	144,610	135,023	136,264	131,630	132,166	132,827	133,490	134,158	134,828	135,503

* INIDE estimations

** Indicate actual number of children vaccinated in past years and updated targets (with either DTP alone or combined)

*** Indicate actual wastage rate obtained in past years

3.2 Confirmed/Revised request for new vaccine (to be shared with UNICEF Supply Division) for 2009

In case you are changing the presentation of the vaccine, or increasing your request; please indicate below if UNICEF Supply Division has assured the availability of the new quantity/presentation of supply.

Nicaragua confirms its request of Pneumococcal vaccine for 2009.

Table 4.4 Portion of supply to be co-financed by the country (and cost estimate, US\$)

		Year 1 2008	Year 2 2009	Year 3 2010	Year 4 2011
Number of vaccine doses	#	71,200	43,100	43,300	58,000
Number of AD syringes	#	N/A	N/A	N/A	N/A
Number of re-constitution syringes	#	N/A	N/A	N/A	N/A
Number of safety boxes	#	800	500	500	650
Total value to be co-financed by country	\$	216,500	131,000	132,000	176,500

N/A: Not applicable.

Table 4.5: Portion of supply to be procured by the GAVI Alliance (and cost estimate, US\$)

		Year 1 2008	Year 2 2009	Year 3 2010	Year 4 2011
Number of vaccine doses	#	650,400	393,500	395,500	383,000
Number of AD syringes	#	N/A	N/A	N/A	N/A
Number of re-constitution syringes	#	N/A	N/A	N/A	N/A
Number of safety boxes	#	7225	4375	4400	4275
Total value to be co-financed by GAVI	\$	3,471,500	2,122,000	2,133,000	2,100,000

N/A: Not applicable.

Note: This amounts in this table do not include GAVI direct support for the introduction plan (a minimum grant of US\$ 100,000.00).

Please refer to http://www.unicef.org/supply/index_gavi.html for the most recent GAVI Alliance Vaccine Product Selection Menu, and review the GAVI Alliance NVS Support Country Guidelines to identify the appropriate country category, and the minimum country co-financing level for each category.

3.3 Confirmed/revised request for injection safety support for the year 2009

2008 will be last year for Injection Safety Support.

Table 8: Estimated supplies for safety of vaccination for the next two years with (Use one table for each vaccine BCG, DTP, measles and TT, and number them from 8a, 8b, 8c, etc. Please use same targets as in Table 5)

		Formula	2009	2010
A	Target if children for Vaccination (for TT: target of pregnant women) (1)	#		
B	Number of doses per child (for TT: target of pregnant women)	#		
C	Number ofdoses	A x B		
D	AD syringes (+10% wastage)	C x 1.11		
E	AD syringes buffer stock (2)	D x 0.25		
F	Total AD syringes	D + E		
G	Number of doses per vial	#		
H	Vaccine wastage factor (3)	Either 2 or 1.6		
I	Number of reconstitution syringes (+10% wastage) (4)	C x H X 1.11/G		
J	Number of safety boxes (+10% of extra need)	(F + I) x 1.11/100		

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area.
- 3 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF
- 4 Only for lyophilized vaccines. Write zero for other vaccines.

Table 9: Estimated supplies for safety of vaccination for the next two years with (Use one table for each vaccine BCG, DTP, measles and TT, and number them from 8a, 8b, 8c, etc. Please use same targets as in Table 5)

		Formula	2009	2010
A	Target if children for Vaccination (for TT: target of pregnant women) (1)	#		
B	Number of doses per child (for TT: target of pregnant women)	#		
C	Number ofdoses	A x B		
D	AD syringes (+10% wastage)	C x 1.11		
E	AD syringes buffer stock (2)	D x 0.25		
F	Total AD syringes	D + E		
G	Number of doses per vial	#		
H	Vaccine wastage factor (3)	Either 2 or 1.6		
I	Number of reconstitution syringes (+10% wastage) (4)	C x H X 1.11/G		
J	Number of safety boxes (+10% of extra need)	(F + I) x 1.11/100		

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area.
- 3 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF
- 4 Only for lyophilized vaccines. Write zero for other vaccines.

Table 8: Estimated supplies for safety of vaccination for the next two years with

		Formula	2009	2010
A	Target if children for Vaccination (for TT: target of pregnant women) (1)	#		
B	Number of doses per child (for TT: target of pregnant women)	#		
C	Number ofdoses	$A \times B$		
D	AD syringes (+10% wastage)	$C \times 1.11$		
E	AD syringes buffer stock (2)	$D \times 0.25$		
F	Total AD syringes	$D + E$		
G	Number of doses per vial	#		
H	Vaccine wastage factor (3)	Either 2 or 1.6		
I	Number of reconstitution syringes (+10% wastage) (4)	$C \times H \times 1.11/G$		
J	Number of safety boxes (+10% of extra need)	$(F + I) \times 1.11/100$		

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area.
- 3 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF
- 4 Only for lyophilized vaccines. Write zero for other vaccines.

Table 9: Estimated supplies for safety of vaccination for the next two years with (Use one table for each vaccine BCG, DTP, measles and TT, and number them from 8a, 8b, 8c, etc. Please use same targets as in Table 5)

		Formula	2009	2010
A	Target if children for Vaccination (for TT: target of pregnant women) (1)	#		
B	Number of doses per child (for TT: target of pregnant women)	#		
C	Number ofdoses	$A \times B$		
D	AD syringes (+10% wastage)	$C \times 1.11$		
E	AD syringes buffer stock (2)	$D \times 0.25$		
F	Total AD syringes	$D + E$		
G	Number of doses per vial	#		
H	Vaccine wastage factor (3)	Either 2 or 1.6		
I	Number of reconstitution syringes (+10% wastage) (4)	$C \times H \times 1.11/G$		
J	Number of safety boxes (+10% of extra need)	$(F + I) \times 1.11/100$		

- 1 Contribute to a maximum of 2 doses for Pregnant Women (estimated as total births)
- 2 The buffer stock for vaccines and AD syringes is set at 25%. This is added to the first stock of doses required to introduce the vaccination in any given geographic area.
- 3 Standard wastage factor will be used for calculation of reconstitution syringes. It will be 2 for BCG, 1.6 for measles and YF
- 4 Only for lyophilized vaccines. Write zero for other vaccines.

5. Checklist

Checklist of completed form:

Form Requirement:	Completed	Comments
Date of submission	June 13 th , 2008	
Reporting Period (consistent with previous calendar year)	2007	
Government signatures	X	
ICC endorsed	-	
ISS reported on	-	
DQA reported on	-	
Reported on use of Vaccine introduction grant	-	
Injection Safety Reported on	X	
Immunisation Financing & Sustainability Reported on (progress against country IF&S indicators)	-	
New Vaccine Request including co-financing completed and Excel sheet attached	X	
Revised request for injection safety completed (where applicable)	-	
HSS reported on	-	
ICC minutes attached to the report	X	
HSCC minutes, audit report of account for HSS funds and annual health sector evaluation report attached to report	-	

6. Comments

ICC/HSCC comments:

~ End ~